Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD

Journal of Attention Disorders

Volumn 16, Issue 8, 2012, Pages 697-705

  Armstrong, Robert B ^a   Damaraju, C V ^b   Ascher, Steve ^b   Schwarzman, Lesley ^b   O'Neill, James ^b   Starr, H Lynn ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

ADHD; duration; methylphenidate

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; SCHOOLS; TREATMENT OUTCOME;

EID: 84867038566     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054711425772     Document Type: Article

References (27)

1. Concerta. Mountain View, CA: Author; 2008:.
2. Diagnostic and statistical manual of mental disorders. 2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.Washington, DC: Author; 2000:.
3. Biederman J.,Boellner S. W.,Childress A.,Lopez F. A.,Krishnan S.,Zhang Y.Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study.Biological Psychiatry. 2007;62:970-976.
4. Brams M.,Muniz R.,Childress A.,Giblin J.,Mao A.,Turnbow J., Silva R.A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: Rapid onset of effect.CNS Drugs. 2008;22:693-704.
5. DosReis S.,Zito J. M.,Safer D. J.,Soeken K. L.,Mitchell J. W.,Ellwood L. C.Parental perceptions and satisfaction with stimulant medications for attention deficit/hyperactivity disorder.Journal of Developmental & Behavioral Pediatrics. 2003;24:155-162.
6. Faraone S. V.,Buitelaar J.Comparing the efficacy of stimulants for ADHD in children and adolescents using the meta-analysis.European Child & Adolescent Psychiatry. 2010;19:353-364.
7. Faraone S. V.,Wigal S. B.,Hodgkins P.Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD.Journal of Attention Disorders. 2007;11:74-82.
8. Greenhill L. L.,Swanson J. M.,Steinhoff K.,Fried J.,Posner K.,Lerner M., Tulloch S.A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD.Journal of the American Academy of Child & Adolescent Psychiatry. 2003;42:1234-1241.
9. McGough J. J.,Wigal S. B.,Abikoff H.,Turnbow J. M.,Posner K.,Moon E.A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with attention deficit/hyperactivity disorder.Journal of Attention Disorders. 2006;9:476-485.
10. Murray D. W.,Bussing R.,Fernandez M.,Hou W.,Garvan C. W.,Swanson J. M.,Eyberg S. M.Psychometric properties of teacher SKAMP ratings from a community sample.Assessment. 2009;16:193-208.
11. Murray D. W.,Childress A.,Giblin J.,Williamson D.,Armstrong R.,Starr H. L.Effects of OROS® methylphenidate on academic, behavioral, and cognitive tasks in children 9 to 12 years of age with attention-deficit/hyperactivity disorder.Clinical Pediatrics. 2011;50:308-320.
12. Pelham W. E.,Gnagy E. M.,Burrows-McLean L.,Williams A.,Fabiano G. A.,Morrisey S. M., Morse G. D.Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.Pediatrics. 2001;107:E105.
13. Pierce P.,Dixon C. M.,Wigal S. B.,McGough J. J.Pharmacokinetics of methylphenidate transdermal system (mts): Results from a laboratory classroom study.Journal of Child and Adolescent Psychopharmacology. 2008;18:355-364.
14. Schachter H. M.,Pham B.,King J.,Langford S.,Moher D.How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.Canadian Medical Association Journal. 2001;165:1475-1488.
15. Schulz E.,Fleischhaker C.,Hennighausen K.,Heiser P.,Oehler K. U.,Linder M., Tracik F.A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.Journal of Child and Adolescent Psychopharmacology. 2010;20:77-85.
16. Smith B. H.,Waschbusch D. A.,Willoughby M. T.,Evans S.The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD).Clinical Child and Family Psychology Review. 2000;3:243-267.
17. Swanson J. M.School-based assessments and interventions for ADD students. Irvine, CA: K. C. Publishing; 1992:.
18. Swanson J. M.,Agler D.,Fineberg E.,Wigal S.,Flynn D.,Fineberg K., Talebi H.Ritalin: Theory and practice. Greenhill L. L.Osman B. B., ed. Larchmont, NY: Mary Ann Liebert; 1999:405-430.
19. Swanson J. M.,Gupta S.,Guinta D.,Flynn D.,Agler D.,Lerner M.,Williams L., Wigal S.Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.Clinical Pharmacology and Therapeutics. 1999;66:295-305.
20. Swanson J. M.,Gupta S.,Lam A.,Shoulson I.,Lerner M.,Modi N., Wigal S.Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies.Archives of General Psychiatry. 2003;60:204-211.
21. Swanson J. M.,Lerner M.,Wigal T.,Steinhoff K.,Greenhill L.,Posner K., Wigal S.The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.Journal of Attention Disorders. 2002;6:S73-S88.
22. Swanson J. M.,Wigal S. B.,Wigal T.,Sonuga-Barke E.,Greenhill L. L.,Biederman J.A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs study).Pediatrics. 2004;113:E206-E216.
23. Wigal S.,Gupta S.,Guinta D.,Swanson J. M.Reliability and validity of the SKAMP rating scale in a laboratory school setting.Psychopharmacology Bulletin. 1998;34:47-53.
24. Wigal S. B.,Kollins S. H.,Childress A. C.,Squires L.A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/ hyperactivity disorder.Child and Adolescent Psychiatry and Mental Health. 2009;3:17.
25. Wigal S. B.,McGough J. J.,McCracken J. T.,Biederman J.,Spencer T. J.,Posner K. L., Tulloch S. J.A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder.Journal of Attention Disorders. 2005;9:275-289.
26. Wigal S. B.,Wigal T. L.The laboratory school protocol: Its origin, use, and new applications.Journal of Attention Disorders. 2006;10:92-111.
27. Wigal S. B.,Wigal T.,Schuck S.,Brams M.,Williamson D.,Armstrong R. B.,Starr H. L.Journal of Child and Adolescent Psychopharmacology. 2011;21:121-131.